Vir Biotechnology/VIR

$10.73

1.71%
-
1D1W1MYTD1YMAX

About Vir Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Ticker

VIR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Marianne De Backer

Employees

587

Headquarters

San francisco, United States

VIR Metrics

BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$4.01
EPS
0.52
Beta
-
Dividend rate
$1.4B
0.515
$27.48
$7.61
960K
12.896
-24.19%
-30.67%
-27.8%
18.033
0.926
0.952
-82.16%
-266.03%
4.11%

What the Analysts think about VIR

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
200.93% upside
High $110.00
Low $12.00
$10.73
Current price
$32.29
Average price target

VIR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-115.8% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$56M
237.13%
Net income
-$65M
-43.74%
Profit margin
-115.8%
-83.31%

VIR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 54.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.45
-$1.22
-$0.86
-$0.48
-
Expected
-$1.20
-$1.21
-$1.01
-$1.05
-$0.90
Surprise
20.5%
1.2%
-14.66%
-54.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vir Biotechnology stock?

Vir Biotechnology (VIR) has a market cap of $1.4B as of May 28, 2024.

What is the P/E ratio for Vir Biotechnology stock?

The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of May 28, 2024.

Does Vir Biotechnology stock pay dividends?

No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Vir Biotechnology dividend payment date?

Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.

What is the beta indicator for Vir Biotechnology?

Vir Biotechnology (VIR) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Vir Biotechnology stock price target?

The target price for Vir Biotechnology (VIR) stock is $32.29, which is 200.93% above the current price of $10.73. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vir Biotechnology stock

Buy or sell Vir Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing